From the Boston Globe: New waiver law fails to quiet criticism over experts' financial ties to drug companies.
Critics say the new transparency has changed little and scientists who have conflicts of interest can still guide FDA decision making. The FDA counters that public health would suffer if the agency bypassed the nation's best scientists because of funding sources.
This sounds a lot like the conflict-of-interest debate the CME community continually is contending with, doesn't it?